Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
G protein-coupled receptor 22 (GPR22) is an orphan class A rhodopsin-like GPCR primarily expressed in the heart and brain, as well as in chondrocytes under some pathological conditions. It possesses seven transmembrane helices and couples to inhibitory G proteins (Gi/Go) in transfected systems, resulting in adenylyl cyclase inhibition. GPR22 is implicated in the regulation of cardiac stress responses, cilia structure and function, and left-right axis development. It is part of a genetic locus associated with osteoarthritis susceptibility, although its direct role in disease remains debated. No endogenous or synthetic ligands for GPR22 have been identified, limiting therapeutic exploration. The receptor’s physiological and pathological significance warrants ongoing research, particularly regarding cardiac protection and ciliogenesis[2][3][4].
For GPR22, transfected cell studies indicate constitutive coupling to Gi/Go proteins, leading to inhibition of adenylyl cyclase and decreased cAMP levels[2][4]. (No approved drugs, so therapeutic mechanism is hypothetical.)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G protein-coupled receptor 22 (GPR22).